Tibet Weixinkang Medicine Co.Ltd(603676) 4 disclose the annual report of 2021 and the report of the first quarter of 2022 on the evening of April 28. In 2021, the company achieved an operating revenue of 1.034 billion yuan, an increase of 44.43% over the previous year; The net profit attributable to the shareholders of the listed company was 959111 million yuan, with a year-on-year increase of 64.16%, of which the net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses was 811549 million yuan, with a year-on-year increase of 105.46%; In the first quarter of this year, the operating revenue was 315 million yuan, a year-on-year increase of 51.62%; The net profit attributable to shareholders of listed companies was 389129 million yuan, a year-on-year increase of 109.71%, of which the net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 379216 million yuan, a year-on-year increase of 107.14%.
In 2021, the sales of Tibet Weixinkang Medicine Co.Ltd(603676) main products showed rapid growth. The company’s Multivitamin (12) for injection is an exclusive domestic variety and a variety in the national medical insurance catalogue (class B). It has won the bid / linked the network in 29 provincial administrative regions. By the end of 2021, the number of hospitals covered had exceeded 1600, maintaining a market share of more than 80% for many years; Multi trace element injection (40ml) is the first imitation, domestic exclusive production variety and national medical insurance catalogue (class B) variety in China. It has won the bid / linked the network in 23 provincial administrative regions, covering more than 100 hospitals, and achieved a sales revenue of 547906 million yuan in the year, with a year-on-year increase of 1596%; China’s first provincial-level hospital to produce various kinds of vitamins, with a year-on-year increase of nearly 2.58 million yuan, covering more than 100 varieties of children’s injection, with an exclusive sales revenue of 2.96 million yuan.
In addition, the newly approved products of the company in recent years, including acetylcysteine solution for respiratory drugs in the national medical insurance catalogue (class B), compound electrolyte injection (V), China’s first imitation and domestic exclusive variety, and mixed sugar electrolyte injection, all grew rapidly at the end of the year. By the end of 2021, the company has completed the market access work of most provincial administrative regions of the country for the above-mentioned new products, and fully tap the market depth and breadth of potential varieties through fine management, targeted force and accurate policy implementation.
In 2021, Tibet Weixinkang Medicine Co.Ltd(603676) increased R & D investment, with R & D investment of 596829 million yuan, an increase of 32% over the previous year. Up to now, the company’s mixed sugar electrolyte injection has obtained the drug registration certificate, one variety of raw and auxiliary materials has passed the review, and the registration status is a; Children’s compound amino acid injection (20AA), multivitamin injection (13) and dopamine hydrochloride injection were accepted for drug registration. The company approved more than 10 R & D projects in 2021, and the product R & D progress met expectations. It is expected that three products will obtain approval conclusions in 2022.
